RxDoctor Payments DataLook up a doctor →

Shiba Nixon

Psychiatric/Mental Health · Clarkston, MINPI 1679041545

Payments from drug & device makers

$60,127in general payments, 2019–2025

Across 792 payments — averaging $75.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$36K
  • AbbVie$14K
  • Alkermes, Inc.$2K
  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • plus $5K from 18 others

What the payments were for

  • Consulting fees$6,75011%
  • Speaking & faculty fees$30,77851%
  • Travel & lodging$7,01112%
  • Food & beverage$15,45626%
  • Education$1320%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,127 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$2,369
Medicare patients
16
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$32,340
Lurasidone Hcl19$5,614
TrintellixVortioxetine Hydrobromide12$5,571
Paliperidone ErPaliperidone11$5,311
Duloxetine Hcl20$486
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine22$478
Mirtazapine21$435
Trazodone Hcl34$404
Quetiapine Fumarate26$392
Buspirone Hcl26$354
Clonazepam24$337
Fluvoxamine Maleate11$307
Divalproex Sodium19$304
Alprazolam50$270
Benztropine Mesylate18$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$13,645$32,34021 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$126$5,57112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Clarkston

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →